Evidence mapPaperPMID 35453142Full record

Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2022

Association of Baseline and Longitudinal Changes in Frailty Burden and Risk of Heart Failure in Type 2 Diabetes-Findings from the Look AHEAD Trial.

Ambarish Pandey, Muhammad Shahzeb Khan, Katelyn Garcia, Felicia Simpson, Judy Bahnson, Kershaw V Patel, Sumitabh Singh, Muthiah Vaduganathan, Alain Bertoni, Dalane Kitzman and 3 more

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Frailty and heart failure: State-of-the-art review.Journal of cachexia, sarcopenia and muscle · 2023
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Ambarish PandeyDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Muhammad Shahzeb KhanDivision of Cardiology, Department of Internal Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Katelyn GarciaDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Felicia SimpsonDepartment of Mathematics, Winston-Salem State University, Winston-Salem, North Carolina, USA.
Judy BahnsonDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Kershaw V PatelDepartment of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.
Sumitabh SinghDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Muthiah VaduganathanDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-0885-1953
Alain BertoniDepartment of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Dalane KitzmanSection on Cardiovascular Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Karen JohnsonDepartment of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0002-3493-4077
Cora E LewisDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Mark A EspelandDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0002-3711-1949
Wake Forest University · USThe University of Texas Southwestern Medical Center · USBrigham and Women's Hospital · USDuke University · USHouston Methodist · USUniversity of Alabama at Birmingham · USUniversity of Tennessee Health Science Center · USWinston-Salem State University · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · UNIVERSITY OF COLORADO DENVER · 1985 to 2005
$37.2M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1985 to 2005
$27.6M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · MASSACHUSETTS GENERAL HOSPITAL · 1985 to 2005
$26.1M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · JOHNS HOPKINS UNIVERSITY · 1986 to 2005
$16.4M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · 1985 to 2005
$16.1M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · UNIVERSITY OF COLORADO DENVER · 1995 to 2025
$7.7M
Louisiana Clinical and Translational Science CenterU54GM104940 · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · 2025 to 2025
$3.9M
Pilot and Feasibility ProgramP30DK072476 · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · 2005 to 2025
$2.2M
CDC HHSNCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000056NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR001346NCRR NIH HHS M01 RR002719NCRR NIH HHS UL1 RR024153NCRR NIH HHS UL1 RR025758NHLBI NIH HHSNIA NIH HHS R03 AG067960NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK072476NIGMS NIH HHS U54 GM104940NIH HHS M01RR000056NIH HHS M01RR00051NIH HHS M01RR0021140NIH HHS M01RR01066NIH HHS M01RR01346NIH HHS M01RR02719NIH HHS P30DK072476NIH HHS P30 DK48520NIH HHS RR025758NIH HHS UL1 RR 024153NIMHD NIH HHSNINR NIH HHSVA
6 · The paper itself

Abstract

backgroundIndividuals with diabetes have a high frailty burden and increased risk of heart failure (HF). In this study, we evaluated the association of baseline and longitudinal changes in frailty with risk of HF and its subtypes: HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF).

methodsParticipants (age: 45-76 years) of the Look AHEAD trial without prevalent HF were included. The frailty index (FI) was used to assess frailty burden using a 35-variable deficit model. The association between baseline and longitudinal changes (1- and 4-year follow-up) in FI with risk of overall HF, HFpEF (ejection fraction [EF] ≥ 50%), and HFrEF (EF < 50%) independent of other risk factors and cardiorespiratory fitness was assessed using adjusted Cox models.

resultsThe study included 5 100 participants with type 2 diabetes mellitus, of which 257 developed HF. In adjusted analysis, higher frailty burden was significantly associated with a greater risk of overall HF. Among HF subtypes, higher baseline FI was significantly associated with risk of HFpEF (hazard ratio [HR] [95% CI] per 1-SD higher FI: 1.37 [1.15-1.63]) but not HFrEF (HR [95% CI]: 1.19 [0.96-1.46]) after adjustment for potential confounders, including traditional HF risk factors. Among participants with repeat measures of FI at 1- and 4-year follow-up, an increase in frailty burden was associated with a higher risk of HFpEF (HR [95% CI] per 1-SD increase in FI at 4 years: 1.78 [1.35-2.34]) but not HFrEF after adjustment for other confounders.

conclusionsAmong individuals with type 2 diabetes mellitus, higher baseline frailty and worsening frailty burden over time were independently associated with higher risk of HF, particularly HFpEF after adjustment for other confounders.

Indexed as

Diabetes Mellitus, Type 2FrailtyHeart FailureAgedHumansPrognosisRisk FactorsStroke VolumeDiabetesFrailtyFrailty indexHeart failure

Identifiers

PMID35453142
PMCPMC9799190
OpenAlexW4224219026

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.